Journal of Analytical Methods in Chemistry / 2019 / Article / Tab 3

Research Article

Quantitative Analysis of Eight Triterpenoids and Two Sesquiterpenoids in Rhizoma Alismatis by Using UPLC-ESI/APCI-MS/MS and Its Application to Optimisation of Best Harvest Time and Crude Processing Temperature

Table 3

Contents of the 10 investigated compounds in 36 batches of RA harvesting samples. AX: alismoxide, C alisol C 23C: alisol C 23-acetate, A alisol A 24A: alisol A 24-acetate, AL: alismol, B alisol B 23B: alisol B 23-acetate, 11-B: 11-deoxyalisol B 11-23B: 11-deoxyalisol B 23-acetate.

Sample codeAXC23CA24AALB23B11-B11-23B

Stage I–10.0220.1530.2880.0220.0130.1720.3100.5380.0940.037
Stage I–20.0170.1640.3450.0250.0170.1580.2900.6980.0830.070
Stage I–30.0170.1950.3290.0180.0120.1290.2570.8450.0930.056
Stage I–40.0250.1740.3510.0280.0100.2120.2930.7490.1100.083
Stage I–50.0150.1520.3180.0210.0150.2840.2660.8650.0970.090
Stage I–60.0210.1730.3230.0170.0150.2000.2840.7520.1260.046

Stage II–10.0250.1350.2460.0200.0210.2160.2850.9660.1160.043
Stage II–20.0180.1220.3350.0200.0200.2180.2460.8310.1000.057
Stage II–30.0220.1190.3140.0270.0200.2360.3070.8290.1050.046
Stage II–40.0230.1200.2760.0280.0270.2390.3300.8830.1160.084
Stage II–50.0280.1430.3030.0220.0240.2050.2910.7620.1230.115
Stage II–60.0220.1470.2880.0220.0240.2170.3520.7670.1320.063

Stage III–10.0300.1390.2380.0290.0260.2260.3260.7470.1040.066
Stage III–20.0320.1280.2850.0350.0390.2220.3030.7180.0990.059
Stage III–30.0340.1110.2380.0280.0310.2100.2670.8020.0880.064
Stage III–40.0330.1230.2160.0300.0300.2190.3011.0490.1040.077
Stage III–50.0340.0940.2910.0290.0340.2310.3260.9240.0900.108
Stage III–60.0260.1230.2250.0270.0340.1970.3600.9980.1040.063

Stage IV–10.0290.0900.1810.0530.0770.2520.3191.0340.1360.041
Stage IV–20.0370.0870.1990.0640.0810.2870.3190.9990.1060.059
Stage IV–30.0310.0880.1600.0550.0700.2710.3630.9930.1370.094
Stage IV–40.0330.0840.1820.0580.0750.2660.4941.2530.1750.091
Stage IV–50.0380.0970.1570.0540.0620.3130.3441.2010.1540.113
Stage IV–60.0360.0920.1700.0620.0680.2600.3681.0780.1340.069

Stage V–10.0290.0710.1500.0330.0340.3760.6341.4880.2160.057
Stage V–20.0300.0810.1730.0310.0380.4120.6101.4770.1950.062
Stage V–30.0280.0730.1590.0390.0370.4230.6741.3990.2300.066
Stage V–40.0320.0840.1560.0280.0410.3790.6391.4600.2520.108
Stage V–50.0280.0830.1460.0320.0310.4020.5651.5440.2340.121
Stage V–60.0320.0800.1590.0360.0330.4330.6071.5380.2110.073

Stage VI–10.0290.1310.2040.0360.0280.3150.4390.7420.1650.047
Stage VI–20.0360.1240.2220.0430.0320.4340.3630.8190.1930.067
Stage VI–30.0350.1020.2350.0310.0240.4570.3430.8280.1860.081
Stage VI–40.0270.1340.1930.0350.0340.4280.3570.7010.1690.098
Stage VI–50.0320.1050.1770.0310.0310.5170.3620.8820.1960.103
Stage VI–60.0300.1000.2040.0350.0300.4450.4360.9490.2080.066

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.